231 related articles for article (PubMed ID: 33693141)
1. 12-Week Effectiveness and Safety of Low-Density Lipoprotein Cholesterol-Lowering Therapy by Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition in Patients With Familial Hypercholesterolemia and Hypercholesterolemia - Data From a Real-World Observational Study of Evolocumab in Japan.
Yokote K; Ako J; Kitagawa K; Inomata H; Sugioka T; Asao K; Shinmura Y; Shimauchi J; Teramoto T
Circ Rep; 2019 May; 1(5):219-227. PubMed ID: 33693141
[No Abstract] [Full Text] [Related]
2. Long-Term Evolocumab in Patients With Familial Hypercholesterolemia.
Santos RD; Stein EA; Hovingh GK; Blom DJ; Soran H; Watts GF; López JAG; Bray S; Kurtz CE; Hamer AW; Raal FJ
J Am Coll Cardiol; 2020 Feb; 75(6):565-574. PubMed ID: 32057369
[TBL] [Abstract][Full Text] [Related]
3. Real-World Effectiveness of PCSK9 Inhibitors in Reducing LDL-C in Patients With Familial Hypercholesterolemia in Italy: A Retrospective Cohort Study Based on the AIFA Monitoring Registries.
Arca M; Celant S; Olimpieri PP; Colatrella A; Tomassini L; D'Erasmo L; Averna M; Zambon A; Catapano AL; Russo P
J Am Heart Assoc; 2023 Nov; 12(21):e026550. PubMed ID: 37850449
[TBL] [Abstract][Full Text] [Related]
4. Evolocumab in patients with homozygous familial hypercholesterolemia in India.
Bansal S; Ruzza A; Sawhney J; Kulkarni G; Iyengar S; Mehta V; Hamer A; Wu Y; Raal FJ
J Clin Lipidol; 2021; 15(6):814-821. PubMed ID: 34750081
[TBL] [Abstract][Full Text] [Related]
5. Proprotein convertase subtilisin/kexin 9 inhibition in patients with familial hypercholesterolemia: Initial clinical experience.
Galema-Boers AMH; Lenzen MJ; Sijbrands EJ; Roeters van Lennep JE
J Clin Lipidol; 2017; 11(3):674-681. PubMed ID: 28506389
[TBL] [Abstract][Full Text] [Related]
6. Long-term safety, tolerability, and efficacy of evolocumab in patients with heterozygous familial hypercholesterolemia.
Hovingh GK; Raal FJ; Dent R; Stefanutti C; Descamps O; Masana L; Lira A; Bridges I; Coll B; Sullivan D
J Clin Lipidol; 2017; 11(6):1448-1457. PubMed ID: 29066265
[TBL] [Abstract][Full Text] [Related]
7. The First Report of a Real-world Experience With a PCSK9 Inhibitor in a Large Familial Hyperlipidemia and Very-high-risk Middle Eastern Population.
Iqbal S; Sabbour HM; Siddiqui MS; Tikriti AA; Santos RD; Buckley A
Clin Ther; 2022 Oct; 44(10):1297-1309. PubMed ID: 36127165
[TBL] [Abstract][Full Text] [Related]
8. Efficacy, safety, and tolerability of evolocumab in pediatric patients with heterozygous familial hypercholesterolemia: Rationale and design of the HAUSER-RCT study.
Gaudet D; Langslet G; Gidding SS; Luirink IK; Ruzza A; Kurtz C; Lu C; Somaratne R; Raal FJ; Wiegman A
J Clin Lipidol; 2018; 12(5):1199-1207. PubMed ID: 30318065
[TBL] [Abstract][Full Text] [Related]
9. Long-term Low-Density Lipoprotein Cholesterol-Lowering Efficacy, Persistence, and Safety of Evolocumab in Treatment of Hypercholesterolemia: Results Up to 4 Years From the Open-Label OSLER-1 Extension Study.
Koren MJ; Sabatine MS; Giugliano RP; Langslet G; Wiviott SD; Kassahun H; Ruzza A; Ma Y; Somaratne R; Raal FJ
JAMA Cardiol; 2017 Jun; 2(6):598-607. PubMed ID: 28291870
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 monoclonal antibody alirocumab vs placebo in patients with heterozygous familial hypercholesterolemia.
Kastelein JJ; Hovingh GK; Langslet G; Baccara-Dinet MT; Gipe DA; Chaudhari U; Zhao J; Minini P; Farnier M
J Clin Lipidol; 2017; 11(1):195-203.e4. PubMed ID: 28391886
[TBL] [Abstract][Full Text] [Related]
11. Preclinical discovery and development of evolocumab for the treatment of hypercholesterolemia.
Khoury E; Brisson D; Gaudet D
Expert Opin Drug Discov; 2020 Apr; 15(4):403-414. PubMed ID: 31973581
[No Abstract] [Full Text] [Related]
12. Eligibility for alirocumab or evolocumab treatment in 1090 hypercholesterolemic patients referred to a regional cholesterol treatment center with LDL cholesterol ≥70 mg/dL despite maximal-tolerated LDL-cholesterol-lowering therapy.
Jetty V; Glueck CJ; Lee K; Goldenberg N; Prince M; Kumar A; Goldenberg M; Anand I; Wang P
Vasc Health Risk Manag; 2017; 13():247-253. PubMed ID: 28740397
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors, alirocumab and evolocumab, a post-commercialization study.
Choi J; Khan AM; Jarmin M; Goldenberg N; Glueck CJ; Wang P
Lipids Health Dis; 2017 Jul; 16(1):141. PubMed ID: 28738813
[TBL] [Abstract][Full Text] [Related]
14. Role of PCSK9 Inhibitors in Patients with Familial Hypercholesterolemia.
Tomlinson B; Patil NG; Fok M; Lam CWK
Endocrinol Metab (Seoul); 2021 Apr; 36(2):279-295. PubMed ID: 33866776
[TBL] [Abstract][Full Text] [Related]
15. Clinical Evaluation Of Evolocumab For The Treatment Of Homozygous Familial Hypercholesterolemia In Chinese Patients.
Huang CC; Charng MJ
Ther Clin Risk Manag; 2019; 15():1209-1216. PubMed ID: 31686828
[TBL] [Abstract][Full Text] [Related]
16. Association Between Circulating Baseline Proprotein Convertase Subtilisin Kexin Type 9 Levels and Efficacy of Evolocumab.
Desai NR; Giugliano RP; Wasserman SM; Gibbs JP; Liu T; Scott R; Sabatine MS
JAMA Cardiol; 2017 May; 2(5):556-560. PubMed ID: 28122070
[TBL] [Abstract][Full Text] [Related]
17. Impact of alirocumab/evolocumab on lipoprotein (a) concentrations in patients with familial hypercholesterolaemia: a systematic review and meta-analysis of randomized controlled trials.
Dai H; Zhu Y; Chen Z; Yan R; Liu J; He Z; Zhang L; Zhang F; Yan S
Endokrynol Pol; 2023; 74(3):234-242. PubMed ID: 37335067
[TBL] [Abstract][Full Text] [Related]
18. Impact of evolocumab treatment on low-density lipoprotein cholesterol levels in heterozygous familial hypercholesterolemic patients withdrawing from regular apheresis.
Kawashiri MA; Nohara A; Higashikata T; Tada H; Nakanishi C; Okada H; Konno T; Sakata K; Hayashi K; Inazu A; Mabuchi H; Yamagishi M
Atherosclerosis; 2017 Oct; 265():225-230. PubMed ID: 28926730
[TBL] [Abstract][Full Text] [Related]
19. Homozygous Familial Hypercholesterolemia Patients With Identical Mutations Variably Express the LDLR (Low-Density Lipoprotein Receptor): Implications for the Efficacy of Evolocumab.
Thedrez A; Blom DJ; Ramin-Mangata S; Blanchard V; Croyal M; Chemello K; Nativel B; Pichelin M; Cariou B; Bourane S; Tang L; Farnier M; Raal FJ; Lambert G
Arterioscler Thromb Vasc Biol; 2018 Mar; 38(3):592-598. PubMed ID: 29284604
[TBL] [Abstract][Full Text] [Related]
20. [Evolocumab (Repatha®) : a human monoclonal antibody against PCSK9 protein as potent cholesterol-lowering therapy].
Wallemacq C
Rev Med Liege; 2017 Nov; 72(11):505-512. PubMed ID: 29171950
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
